• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Black Titan Corporation

    5/15/26 4:50:07 PM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BTTC alert in real time by email
    6-K 1 form6-k.htm 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the months of April and May 2026

     

    Commission File No. 001-42880

     

    BLACK TITAN CORPORATION

    (Registrant’s Name)

     

    Level 8, Unit 8-02 The Bousteador, 10, Jalan PJU 7/6

    Mutiara Damansara, 47800 Petaling Jaya

    Selangor Darul Ehsan, Malaysia

    (Address of Principal Executive Offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     

     

     

    Material Agreements

     

    Settlement Agreement and Mutual Release

     

    In January 2026, Mr. Lazar, the former Chief Executive Officer of Titan Pharmaceuticals, Inc. (“TTNP”), the predecessor company to Black Titan Corporation (“Black Titan”), asserted a claim against the Company alleging an entitlement to a special bonus arising in connection with the merger that closed on October 1, 2025. The Company disputed both the validity and the amount of Mr. Lazar’s claim and the amount involved, and the parties remained in active dispute through the first quarter of 2026.

     

    Following negotiations, Black Titan executed a Settlement and Release Agreement with Mr. Lazar, pursuant to which they agreed to fully and finally resolve the disputed claim through a one-time payment of US$800,000 (the “Settlement Amount”). The Settlement Amount was determined in April 2026 and paid in full on April 15, 2026, and Mr. Lazar acknowledged that the Group owes no further amounts.

     

    Each of Black Titan and Mr. Lazar also agreed to a mutual release of any claims they may have against each other.

     

    Related Party Transaction.

     

    ARC Group International Limited (“ARC”), a significant shareholder of Black Titan, provided the funds for payment of the Settlement Amount.

     

    In satisfaction of the payment of the Settlement Amount by ARC directly to Mr. Lazar, Black Titan has issued 800 preferred shares of $0.001 par value each in Black Titan, which are designated as series B preferred shares (the “Series B Shares”) to ARC, pursuant to the terms of a Securities Purchase Agreement, May 8, 2026. The Series B Shares are convertible, at any time, and from time to time, into ordinary shares of Black Titan at a conversion price of 80% of the 5-day VWAP immediately preceding the applicable conversion date. Black Titan will register the ordinary shares underlying the Series B Shares within sixty (60) days after the closing date of the sale of the Series B shares, and to use commercially reasonable efforts to have such registration statement declared effective as soon as practicable thereafter.

     

    The Series B Shares have no voting rights. However, as long as any Series B Shares are outstanding, the Black Titan shall not, whether by amendment, merger, or any other means, without the affirmative consent of the holders of a majority of the then outstanding Series B Shares:

     

      ● alter or change adversely the powers, preferences or rights attached to the Series B Shares;
         
      ● amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Shares;
         
      ● increase the number of Series B Shares which the Company may issue;
         
      ● enter into or consummate any fundamental transaction; or
         
      ● enter into any agreement with respect to any of the foregoing.

     

    The Audit Committee of Black Titan has ratified the related party transaction.

     

    2

     

     

    Amendment to Convertible Note Transaction Documents

     

    As previously disclosed in the Report on Form 6-K filed in January 2026, on January 16, 2026, Black Titan entered into a Securities Purchase Agreement with an institutional investor (the “Buyer”) relating to the issuance and sale of a series of original issue discount senior, unsecured convertible notes for up to an aggregate principal amount of $200,000,000, which are convertible into ordinary shares of Black Titan. On the same date, Black Titan issued an initial note in the principal amount of $1,515,000 and a registration rights agreement.

     

    On May 11, 2026, we entered into amendment agreements with the Buyer to amend the (i) Securities Purchase Agreement, (ii) Registration Rights Agreement; and (iii) Initial Note (collectively, the “Convertible Note PIPE transaction documents”), which were initially executed on January 16, 2026 in connection with the closing of the Convertible Notes PIPE transaction, to (x) remove all references to the defined term “Adjusted Floor Price” from the Convertible Note PIPE transaction documents, and to (y) amend and restate certain defined terms to remove references to “Adjusted Floor Price” from the following definitions in the Initial Note:

     

      (1) “Alternate Conversion Floor Amount” means an amount in cash, to be delivered by wire transfer of immediately available funds pursuant to wire instructions delivered to the Company by the Holder in writing, equal to the product obtained by multiplying (A) the VWAP on the day the Holder delivers the applicable Conversion Notice and (B) the difference obtained by subtracting (I) the number of Ordinary Shares delivered (or to be delivered) to the Holder on the applicable Share Delivery Deadline with respect to such Alternate Conversion from (II) the quotient obtain by dividing (x) the applicable Conversion Amount that the Holder has elected to be the subject of the applicable Alternate Conversion, by (y) the applicable Alternate Conversion Price without giving effect to clause (ii)(x) of such definition.
         
      (2) “Excluded Securities” means (i) Ordinary Shares or standard options to purchase Ordinary Shares issued to directors, officers, employees or consultants of the Company for services rendered to the Company in their capacity as such pursuant to an Approved Stock Plan (as defined above) or as inducement awards granted outside of an Approved Stock Plan, provided that (A) all such issuances (taking into account the Ordinary Shares issuable upon exercise of such options) after the Subscription Date pursuant to this clause (i) do not, in the aggregate, exceed more than 20% of the Ordinary Shares issued and outstanding immediately prior to the Subscription Date and (B) the exercise price of any such options is not lowered, none of such options are amended to increase the number of shares issuable thereunder and none of the terms or conditions of any such options are otherwise materially changed in any manner that adversely affects any of the Buyers; (ii) Ordinary Shares issued upon the conversion or exercise of Convertible Securities or Options (other than standard options to purchase Ordinary Shares issued pursuant to an Approved Stock Plan that are covered by clause (i) above) issued prior to the Subscription Date, provided that the conversion price of any such Convertible Securities (other than standard options to purchase Ordinary Shares issued pursuant to an Approved Stock Plan that are covered by clause (i) above) is not lowered, none of such Convertible Securities or Options (other than standard options to purchase Ordinary Shares issued pursuant to an Approved Stock Plan that are covered by clause (i) above) are amended to increase the number of shares issuable thereunder and none of the terms or conditions of any such Convertible Securities or Options (other than standard options to purchase Ordinary Shares issued pursuant to an Approved Stock Plan that are covered by clause (i) above) are otherwise materially changed in any manner that adversely affects any of the Buyers; and (iii) the Ordinary Shares issuable upon conversion of the Notes or otherwise pursuant to the terms of the Notes; provided, that the terms of the Notes are not amended, modified or changed on or after the Subscription Date (other than antidilution adjustments pursuant to the terms thereof in effect as of the Subscription Date).
         
      (3) “Floor Price” means $0.3248 (as adjusted for stock splits, stock dividends, stock combinations, recapitalizations and similar events), which price is no less than 20% of the closing price of the Ordinary Shares on the Trading Day immediately prior to the execution of the Transaction Documents.”
         
      (4) “Interest Conversion Price” means, as of any date of determination, the lower of (x) the Conversion Price then in effect on the applicable Interest Date or (y) 90% of the lowest daily VWAP of the Ordinary Shares during the ten (10) Trading Days prior to the applicable Interest Date, but shall in no event be lower than the Floor Price then in effect.”

     

    Other Events

     

    On May 12, 2026, Black Titan released a press release with updates to certain companies in the digital assets industry. The full text of the press release is attached as Exhibit 99.1.

     

    Exhibits

     

    4.1 Certificate of Designations for Series B Preferred Shares of Black Titan Corporation
    10.1 Settlement and Release Agreement dated April 2, 2026, with David Lazar
    10.2 First Amendment to the Securities Purchase Agreement, dated May 11, 2026
    10.3 First Amendment to the Registration Rights Agreement, dated May 11, 2026
    10.4 First Amendment to the Senior Unsecured Convertible Note, dated May 11, 2026
    99.1

    Press Release dated May 12, 2026

     

    3

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Black Titan Corporation
         
      By: /s/ Chay Weei Jye
      Name: Chay Weei Jye
      Title: Co-Chief Executive Officer

     

    Dated: May 15, 2026

     

    4

     

    Get the next $BTTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BTTC
    SEC Filings

    View All

    SEC Form 6-K filed by Black Titan Corporation

    6-K - Black Titan Corp (0002034400) (Filer)

    5/15/26 4:50:07 PM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Black Titan Corporation

    EFFECT - Black Titan Corp (0002034400) (Filer)

    5/15/26 12:15:18 AM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form F-1/A filed by Black Titan Corporation

    F-1/A - Black Titan Corp (0002034400) (Filer)

    5/12/26 4:17:42 PM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BTTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to Adjustments

    SUMMIT, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Aterian, Inc. (NASDAQ:ATER) ("Aterian" or the "Company"), a consumer products company, today announced separate transactions related to its previously announced Strategic Alternative Process. Sale of E-Commerce Brand Portfolio (the "Asset Sale") The Company has signed a definitive agreement with Trademark Global, LLC ("Trademark") for the sale of assets associated with its marquee brands: Mueller Living, PurSteam, hOmeLabs, Squatty Potty, Healing Solutions, and Photo Paper Direct. Under the terms of the purchase agreement for the Asset Sale, Trademark will acquire the worldwide business of sourcing, marketing, and selling products under th

    4/28/26 8:00:00 AM ET
    $ATER
    $BGMS
    $BTTC
    Home Furnishings
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BLACK TITAN CORPORATION APPOINTS CZHANG LIN AS CO-CHIEF EXECUTIVE OFFICER

    NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Black Titan Corporation (NASDAQ:BTTC) (the "Company" or "Black Titan") today announced the appointment of Czhang Lin as Co-Chief Executive Officer, further strengthening the Company's leadership team as it accelerates its strategic expansion into the digital asset and blockchain sectors. Mr. Lin brings deep expertise in the cryptocurrency and blockchain ecosystem, with a track record of investing in and advising high-growth Web3 projects around the world since 2017. He has collected a vast network over the last 8 years by investing in projects or taking key roles in various funds, that include Binance labs and now currently serves as investment

    11/12/25 8:30:00 AM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Black Titan Corporation seeks to explore Long-Term Strategic Crypto Initiatives with potential Strategic Investments in Digital Currencies

    NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Black Titan Corporation. (NASDAQ:BTTC) (the "Company" or "Black Titan"), today announced plans to seek long-term strategic crypto initiatives with potential strategic investments in digital currencies. Black Titan is exploring the utilization of a digital currency holding strategy to invest in and capitalize on cryptocurrency opportunities. Black Titan is actively exploring additional investments to expand its portfolio through direct coin acquisitions, mining, and fintech-related mergers and acquisitions. Chay W. J., CEO of Black Titan, remarked, "The approach of leveraging debt, equity, and cash flow to build Crypto holdings has delivered stro

    10/6/25 4:15:00 PM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BTTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Flores Garcia Francisco Osvaldo

    3 - Black Titan Corp (0002034400) (Issuer)

    3/19/26 8:14:02 AM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Mokhtar Firdauz

    3 - Black Titan Corp (0002034400) (Issuer)

    3/19/26 8:11:05 AM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Chiam Brynner Zet Han

    3 - Black Titan Corp (0002034400) (Issuer)

    3/19/26 8:07:23 AM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BTTC
    Leadership Updates

    Live Leadership Updates

    View All

    Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to Adjustments

    SUMMIT, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Aterian, Inc. (NASDAQ:ATER) ("Aterian" or the "Company"), a consumer products company, today announced separate transactions related to its previously announced Strategic Alternative Process. Sale of E-Commerce Brand Portfolio (the "Asset Sale") The Company has signed a definitive agreement with Trademark Global, LLC ("Trademark") for the sale of assets associated with its marquee brands: Mueller Living, PurSteam, hOmeLabs, Squatty Potty, Healing Solutions, and Photo Paper Direct. Under the terms of the purchase agreement for the Asset Sale, Trademark will acquire the worldwide business of sourcing, marketing, and selling products under th

    4/28/26 8:00:00 AM ET
    $ATER
    $BGMS
    $BTTC
    Home Furnishings
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BLACK TITAN CORPORATION APPOINTS CZHANG LIN AS CO-CHIEF EXECUTIVE OFFICER

    NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Black Titan Corporation (NASDAQ:BTTC) (the "Company" or "Black Titan") today announced the appointment of Czhang Lin as Co-Chief Executive Officer, further strengthening the Company's leadership team as it accelerates its strategic expansion into the digital asset and blockchain sectors. Mr. Lin brings deep expertise in the cryptocurrency and blockchain ecosystem, with a track record of investing in and advising high-growth Web3 projects around the world since 2017. He has collected a vast network over the last 8 years by investing in projects or taking key roles in various funds, that include Binance labs and now currently serves as investment

    11/12/25 8:30:00 AM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care